Horizon Therapeutics Public Limited Co (fka HZNP)

[surf1944]

7:31AM Horizon Pharma receives marketing authorization for DUEXIS from the United Kingdom medicines and Healthcare Products Regulatory Agency (HZNP) 2.05 : Co announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for DUEXIS (ibuprofen/famotidine) for the symptomatic treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis in patients who require regular treatment with high dose ibuprofen administered three times a day and who are at risk of developing non-steroidal anti-inflammatory drug associated gastric and/or duodenal ulcers. Horizon is seeking to license rights to DUEXIS in Europe to one or more commercial partners.